Tang Capital Management LLC Takes Position in COMPASS Pathways plc (NASDAQ:CMPS)

Tang Capital Management LLC bought a new stake in COMPASS Pathways plc (NASDAQ:CMPS) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 1,000,000 shares of the company’s stock, valued at approximately $3,780,000. Tang Capital Management LLC owned 1.46% of COMPASS Pathways at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CMPS. Affinity Asset Advisors LLC lifted its position in COMPASS Pathways by 183.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company’s stock valued at $3,215,000 after acquiring an additional 550,000 shares in the last quarter. Barclays PLC lifted its position in COMPASS Pathways by 2.1% in the 4th quarter. Barclays PLC now owns 419,194 shares of the company’s stock valued at $1,585,000 after acquiring an additional 8,718 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in COMPASS Pathways by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after acquiring an additional 26,787 shares in the last quarter. Renaissance Technologies LLC lifted its position in COMPASS Pathways by 161.3% in the 4th quarter. Renaissance Technologies LLC now owns 212,700 shares of the company’s stock valued at $804,000 after acquiring an additional 131,300 shares in the last quarter. Finally, Altium Capital Management LLC bought a new position in COMPASS Pathways in the 4th quarter valued at about $5,384,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Price Performance

COMPASS Pathways stock opened at $3.98 on Friday. COMPASS Pathways plc has a 52 week low of $2.49 and a 52 week high of $8.54. The company’s 50 day moving average price is $3.35 and its two-hundred day moving average price is $3.94. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market cap of $369.54 million, a P/E ratio of -1.81 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03. On average, equities analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group dropped their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research report on Monday, May 12th. Finally, Cantor Fitzgerald raised shares of COMPASS Pathways to a “strong-buy” rating in a research report on Tuesday, May 13th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, COMPASS Pathways currently has a consensus rating of “Buy” and a consensus target price of $20.20.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.